Overview

Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

Status:
Completed
Trial end date:
2020-07-23
Target enrollment:
Participant gender:
Summary
This is a 12 month safety study to evaluate the safety of repeated doses of NRL-1
Phase:
Phase 3
Details
Lead Sponsor:
Neurelis, Inc.
Treatments:
Diazepam